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Background: Acetyl-CoA is a key metabolic intermediate with roles in the production of energy and biomass, as
well as in metabolic regulation. It was recently found that acetate is crucial for maintaining acetyl-CoA production
in hypoxic cancer cells. However, the availability of free acetate in the tumor environment and how much tumor
cells consume remains unknown. Similarly, much is still to be learned about changes in the dynamics and
distribution of acetylation in response to tumor-relevant conditions. The analysis of acetate is non-trivial, and to
help address these topics, we developed a rapid and robust method for the analysis of both free and bound acetate
in biological samples.
Results: We developed a sensitive and high-throughput method for the analysis of acetate based on alkylation to its
propyl derivative and gas chromatography-mass spectrometry. The method facilitates simultaneous quantification
of both 12C- and 13C-acetate, shows high reproducibility (< 10 % RSD), and has a wide linear range of quantification
(2–2000 μM). We demonstrate the method’s utility by measuring free acetate uptake by cultured cancer cells and by
quantifying total acetylation (using hydrolysis) in separate cellular compartments. Additionally, we measure free acetate
in tissues and bio-fluids and show that there are considerable differences in acetate concentrations between organs
in vivo, providing insights into its complex systemic metabolism and availability for various types of tumors.
Conclusions: Our approach for the quantification of acetate is straightforward to implement using widely available
equipment and reagents, and will aid in in-depth investigation of various aspects of acetate metabolism. It is also
readily adaptable to the analysis of formate and short-chain fatty acids, making it highly relevant to the cancer
metabolism community.
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Cancer cells have an incessant drive to proliferate, caus-
ing an unremitting demand for cellular building blocks
to make new cells [1–4]. Among these building blocks
are fatty acids that are incorporated into membrane
lipids. Cancer cells acquire a significant proportion of
their non-essential fatty acids through de novo synthesis
[5–7]. The precursor for fatty acid synthesis is acetyl-
CoA (AcCoA), of which the 2-carbon acetyl units are
ligated to make the fatty acid palmitate, which in turn is* Correspondence: Jurre.kamphorst@glasgow.ac.uk
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generate a diversity of fatty acids.
AcCoA is located centrally in both catabolic and ana-
bolic pathways. Therefore, it also acts as a rheostat of a
cell’s metabolic state. This occurs in part by a direct ef-
fect of AcCoA on enzyme activity through allosteric
regulation and other means [8, 9]. Additionally, enzyme
activity is modulated by protein acetylation. Indeed,
most enzymes of central carbon metabolism are acety-
lated to control activity [10]. Acetylation is especially
prominent on histones and is important for controlling
gene expression [11–13]. Based on this, it is not surpris-
ing that acetyl-transferases, sirtuins, and histone deace-
tylases have been found to play important roles in
tumorigenesis [14, 15].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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have a high demand for AcCoA. In nutrient and oxygen-
replete conditions, this demand is largely met by mito-
chondrial AcCoA production from glucose carbon. This
AcCoA is then used to make citrate, which in turn is
transported to the cytosol to produce cytosolic AcCoA.
In hypoxic conditions, however, most glucose is shunted
towards lactate, and AcCoA production from glucose is
diminished [16, 17]. The observation of a concomitant
increase in citrate M+5 labeling from U-13C-glutamine
has led to the finding that glutamine, through reductive
carboxylation, is used to make AcCoA [16, 18]. However,
the exact net carbon contribution is still debated [19].
Recently, a third substrate was found to sustain AcCoA
synthesis, especially in hypoxic and highly glycolytic
tumor cells: acetate [17, 20, 21]. AcCoA synthesis from
acetate occurs through AcCoA synthetases (ACSS), and
the nucleocytosolic ACSS2 was found to be important
for maintaining tumor growth [20, 21].
As we discussed previously, while the fractional label-
ing of nucleocytosolic AcCoA from U-13C-acetate has
been determined [17], this may not reflect the actual
carbon contribution. The 2-carbon units from AcCoA
could exchange back and forth with acetate, causing
mixing of label that is not a representative of net flux. In
extreme cases, significant labeling of AcCoA, and hence
fatty acids, from acetate may be observed without a net
carbon contribution [19]. Conversely, a potential exchange
between intermediates from other substrates, like glutam-
ine, would lead to an under-representation of the contri-
bution from acetate. Therefore, an exact understanding of
acetate’s importance as a carbon source requires direct
analysis of acetate uptake by cells. Such a method could
additionally be used for analysis of acetylation dynamics in
cells, a subject that remains understudied.
Over the years, methods based on a number of princi-
ples have been developed for the analysis of acetate. An
older method includes enrichment of acetate using a
distillation-diffusion unit based on mixing the sample
with anhydrous sodium sulfate and sulfuric acid and
heating in the distillation bulb [22]. The then formed
acetic acid is captured by water in the receiving tube and
then measured using radioactivity (using 14C-acetate) [23]
or flame ionization gas chromatography [24, 25]. Later
on, enzymatic assays and NMR gained popularity.
These approaches facilitate acetate quantitation but
lack the combined strength of high sensitivity, the abil-
ity to use stable-isotopes to determine turnover, and
short analysis times. The use of mass spectrometry is
promising in this regard, but due to the small size of
acetate, it depends on a reliable derivatization ap-
proach. Over the recent years, a number of papers ad-
dressing this have been published, based on silylation
and alkylation [26–28].Here, we present a GC-MS-based method that was
fully optimized and validated for the accurate determin-
ation of both free and bound acetate. This method is
based on alkylation of acetate to propyl-acetate. It is
rapid in terms of sample preparation and analysis and
was found to behave favorably in terms of accuracy, re-
peatability, and linear concentration range. It also mini-
mizes background levels of acetate, a problem that can
easily complicate the analysis of this metabolite and of
longer chain fatty acids. We demonstrate the method’s
utility by studying uptake of U-13C-acetate from the
medium by cultured cancer cells. We also show that free
acetate levels differ considerably between organs, in vivo,
indicating that acetate availability for tumors depends on
their anatomical location. In addition, we determine the
bound acetate content of the cell and its sub-cellular
fractions (i.e., nuclear bound acetate). Finally, we show
that by using alternative alkylating agents, other com-
pounds with clear relevance in cancer, like formate, can
also be measured. Thus, the method described here will
facilitate in-depth investigation into the role of acetate,
and with slight modification, of other short-chain fatty
acids in cancer.
Methods
Chemicals
Methyl chloroformate (MCF), methyl tert-butyl ether
(MTBE), sodium hydroxide, concentrated hydrochloric
acid, pyridine, 1-propanol, propyl-acetate, N-acetyl-L-
aspartic acid (NAA), N-acetyl-L-cysteine (NAC), es-
sential free fatty acid and globulin free bovine serum
albumin (BSA), sodium acetate, sodium U-13C-acetate,
and sodium 2H3-acetate, all of analytical grade, were
from Sigma-Aldrich.
Cell culture
A549 human lung carcinoma cells were from ATCC,
were regularly tested for Mycoplasma, and were pas-
saged in Dulbecco’s modified Eagle medium (DMEM;
HyClone, GE Healthcare) containing 10 % fetal bovine
serum (FBS; Gibco, Thermo Fisher Scientific) and split
at 80 % confluence. Experiments were performed in
DMEM with 10 mM glucose and 2 mM glutamine (ex-
periment culture medium). For determining U-13C-acetate
uptake, A549 cells were plated a day before the experi-
ment in 6-well culture plates in medium with 10 % dia-
lyzed FBS (HyClone, GE Healthcare). At 0 h, medium
was replaced with experiment culture medium with
same serum conditions and with sodium U-13C-acetate
(0.5 mM). Samples were collected at multiple time
points (0, 24, 48, and 72 h) and spun down at 2500g for
5 min to remove cell debris. To study the effect of his-
tone deacetylase (HDAC) inhibitors, cells were incu-
bated for 4 h with 50 μM panobinostat (Cayman
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packed cell volume (PCV) tubes (VoluPac, Sartorius).
For hypoxia experiments, cells were cultured in pre-
equilibrated medium in hypoxic glovebox (Whitley
Scientific) maintained at 37 °C, 5 % CO2, and 1 % O2 a
day before the experiment.
Extraction of total acetate from cells
For quantification of bound acetate in various cellular
fractions (i.e., nuclear and residual cellular fractions), we
used a nuclear extraction kit (Merck Millipore) as per
the vendor’s protocol. Acidic extraction of histones was
performed as described previously [29]. For the fraction-
ation procedures, the cells were washed with cold PBS
and lysed with buffers provided by the kit, all containing
50 mM nicotinamide (Sigma) and 10 mM sodium butyr-
ate (Sigma). The efficiency of fractionation was verified
by western blot, using NuPage gels (Invitrogen, Life
Technologies) and nitrocellulose membranes. Lysates for
western blot were prepared in RIPA buffer (Pierce) with
a protease inhibitor cocktail (Sigma). Tubulin (1:2500;
Sigma, T5201) and TATA-binding protein (TBP; 1:2500;
Abcam, ab63766) were used as cytosolic and nuclear
markers, respectively. Histone fraction purity was con-
firmed by staining with Ponceau S (BioRad). Protein
concentrations for the isolated cellular fractions were
determined using Bradford Protein Assay Kit (Bio-Rad).
Extraction of total (free and bound) cellular acetate
was performed by saponification of the cell pellet in so-
dium hydroxide. Cell pellets obtained by trypsinizing
cells in 6-well plates were transferred to pre-chilled (ice
temperature) microfuge tubes, centrifuged at 100g and
4 °C for 5 min and washed with ice cold PBS containing
50 mM nicotinamide and 10 mM sodium butyrate (2×),
and finally centrifuged at 4 °C at 500g for 5 min. Bound
acetate hydrolysis was performed by saponifying 50 μL
of the extract through overnight incubation with
200 μL 10 M sodium hydroxide in a microfuge tube
at 95 °C. Each sample was then cooled on ice before
adding 150 μL of concentrated hydrochloric acid,
followed by addition of 40 μL 1 mM internal standard
sodium 2H3-acetate and drying by SpeedVac. The
dried samples were reconstituted in 200 μL of water
and further derivatized as below.
Quantification of free acetate in tissues and bio-fluids
All animal work was performed in accordance with the
European Directive 2010/63/EU and approved by ethical
review process from the University of Glasgow. The
heart, spleen, pancreas, kidney, liver, thymus, and lung
tissues as well as urine and plasma were obtained from
C57BL/6 mice (n = 7 for tissues and n = 5 for plasma
and urine). Samples were snap-frozen on dry ice directly
after collection, and tissues were ground using a mortarand pestle (both dry ice temperature). Aliquots of
ground tissue (30–150 mg) were subsequently trans-
ferred to −20 °C Precellys lysing tubes (KT03961-1-003)
containing 40 μL of 1 mM sodium 2H3-acetate and
200 μL methanol-water (1:1, v/v), for homogenization
using a Precellys24 system (Precellys). The homogenates
were then transferred into ice-chilled microfuge tubes,
the lysing tubes were rinsed with 400 μL methanol-
water (1:1, v/v) and fractions combined. The samples
were centrifuged at maximum speed at −5 °C for
15 min, and supernatant was transferred to a new micro-
fuge tube and dried by SpeedVac. Dried tissue extracts
were resuspended in 200 μL water and derivatized as
below. Mouse urine and plasma samples were directly
subjected to derivatization using the procedure below.
Human plasma samples were provided by Professor Iain
McInnes, University of Glasgow, under the Ethics appli-
cation 200150019 “The isolation of cells and soluble
mediators from the blood of healthy volunteers”.
Sample derivatization and analysis
Chemical derivatization of acetate
Note: because of the organic solvents and reagents, the
derivatization should be performed in a fume hood. 200
μL of sample was added to a 2 mL microfuge tube,
followed by addition of 40 μL of 1 mM internal standard
sodium 2H3-acetate (unless this was already added),
50 μL of 1-propanol, and 50 μL of pyridine. The tube
was then placed on ice for 5 min. 100 μL of 1 M sodium
hydroxide was then added, immediately followed by
30 μL MCF and vigorous vortexing for 20 s. As gas
builds up in the microfuge tube during the derivatization
reaction, keep the lid closed with one finger and care-
fully open after vortexing to relieve pressure or keep the
lid open during vortexing. After vortexing, 300 μL of
MTBE was added, the sample vortexed for another 20 s,
and centrifuged at 10,000g for 5 min. 200 μL microliters
of the resulting upper layer was transferred to a GC vial
for analysis.
Acetate quantification by GC-MS
The acetate samples were analyzed with an Agilent
7890B GC system coupled to a 7000 Triple Quadrupole
GC-MS system. The column was Phenomenex ZB-1701
column (30 m × 0.25 mm × 0.25 μm), with an oven pro-
gram as described in Table 1. Samples (2 μL) were
injected using split mode (0.5 bar, 25 mL/min split flow).
The column gas flow was held at 1.0 mL of He per min.
The temperature of the inlet was 280 °C, the interface
temperature 230 °C, and the quadrupole temperature
200 °C. The column was equilibrated for 2 min before
each analysis. The mass spectrometer was operated in
scan mode between 2.2 and 2.7 min with a mass
range of 30–150 AMU at 1.47 scans/s. Agilent Mass
Table 1 GC temperature program for acetate analysis
Start temperature
(°C)
Ramp (°C/min) End temperature
(°C)
Hold time (min)
45 – 45 0.8
45 25 60 0
60 50 190 0
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MetabQ software were employed for automated data
processing using peak heights of m/z 61, 63, and 64
ions used to quantify 12C, U-13C, and 2H3-acetate, re-
spectively (the peak shapes were consistently highly
symmetric, and using either peak area or peak heights
gave equivalent results) [30]. Peak heights of 12C and
U-13C acetate were compared to the 2H3-acetate peak
height, and absolute concentrations were obtained
from a calibration curve.
Results and discussion
Method description
We developed a robust and high-throughput method for
absolute acetate quantification in biological samples. The
method is based on derivatization using an established re-
action with methyl chloroformate (MCF) [31, 32]. After
sequentially adding internal standard, 1-propanol, pyri-
dine, and sodium hydroxide, the derivatization reaction isFig. 1 Schematic representation of the workflow for rapid acetate quantific
2H3-acetate, pyridine (Py), and 1-propanol (1-PrOH) followed by derivatizatio
the derivatization, the sample was mixed with methyl tert-butyl ether (MTB
Thereafter, the sample was spun down and the top MTBE layer was transfeinitiated by adding MCF as soon as possible. The chemical
modification occurs in basic conditions due to the pres-
ence of sodium hydroxide, while pyridine keeps the reac-
tion system homogeneous as MCF does not dissolve in
water alone (Fig. 1). 1-Propanol is used as a coupling
reagent to produce propyl-acetate (Fig. 2). When sodium
hydroxide is added to the cooled sample immediately
prior to MCF addition, no hydrolysis occurs (see below).
Alkylation of acetate with MCF facilitates rapid further
modification of acetate in water-based conditions. In this
case, the acetate-MCF intermediate (I) is attacked by the
alcohol (1-propanol), and the resultant intermediate (II)
undergoes further rearrangements, leading to the forma-
tion of propyl-acetate. Such derivatization approaches
using the chloroformate family of reagents are well
described [27, 31]. To quantify the yield of the derivatiza-
tion and subsequent extraction into MTBE, we compared
the MS signal intensity of 1 mM of acetate alkylated to
propyl-acetate to an equimolar concentration of commer-
cially obtained propyl-acetate in MTBE. Based on this, we
found the recovery to be 95.5 ± 1.57 % (Additional file 1:
Table S1).
The derivatization reaction with MCF is vigorous and
exothermic, producing gases (hydrochloric gas, carbon
dioxide) that cause pressure to increase within the tube.
We therefore recommend following general health and
safety rules when performing chemical derivatization,ation. A sample aliquot was mixed with internal standard sodium
n by adding sodium hydroxide and methyl chloroformate (MCF). After
E) and vortexed in order to extract acetate derivative (propyl-acetate).
rred into GC vial for further GC-MS analysis
Fig. 2 Chemical derivatization of acetate. Using methyl chloroformate (MCF), the carboxylic group of acetate is converted to a propyl ester:
acetate first attacks MCF and the resulting intermediate (I) is then attacked by alcohol (1-propanol), generating a second intermediate (II), which
undergoes further rearrangements to form propyl-acetate
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carrying out the reaction in a fume hood. To minimize
the vigor of the reaction and hence pressurization, it is
important to incubate the sample on ice (5 min) prior to
derivatization. We recommend keeping the lid closed
with one finger during vortexing and to carefully open
the tube afterwards (a “popping” sound can be heard).
Alternatively, the tube can be kept opened during the
vortexing, depending on the researcher’s preference (we
find that the tube’s contents do not spill when handled
carefully). Afterwards, the derivatized acetate (propyl-
acetate) can be easily extracted into organic solvent
(MTBE) followed by the GC-MS analysis (Fig. 1).
Other primary alcohols (e.g., methanol and ethanol
producing methyl and ethyl acetate, respectively) also
can be used for derivatization. However, we found that
with our mid-polar GC column (which we find to be
very suitable for the analysis of a broad range of metabo-
lites), propyl-acetate provides the optimal peak shape
and retention time for rapid analysis. The sample prep-
aration protocol described here is very rapid with a total
derivatization time of a less than 1 min per sample.
Together with the short GC-MS program with a total
run time of 4 min per sample, this facilitates high-
throughput analysis. While the acetate isotopologues
12C-acetate, U-13C-acetate, and 2H3-acetate have almost
identical retention times, their peaks can be easily
deconvoluted using specific ions (Fig. 3). As is generally
observed in GC analysis of deuterated analytes, the 2H3-
acetate derivative has a slightly shorter retention time
due to inverse isotope effect [33]. Ions m/z 61, 63, and
64 for 12C2-acetate, U-
13C2-acetate, and
2H3-acetate, re-
spectively, were used for absolute quantification and
showed optimal linear response.Method validation
To assess the repeatability of the sample preparation and
analysis procedure, we determined the relative standard
deviation (RSD) for 12C- and U-13C-acetate in freshly
prepared standards at 50, 200, and 1000 μM for the
respective acetate isotopologues. The method showed
excellent repeatability with a RSD < 5 % for standards
and < 10 % for biological samples (Additional file 1:
Table S2). The linear range of quantification was
assessed by analysis of serially diluted standards of
both 12C- and U-13C-acetate within the range 2–
2000 μM. We were unable to determine the limit of
detection (LOD) for 12C-acetate as a background acet-
ate signal of approximately 15 μM was always present
in our samples, even though only reagents of the
highest purity were used. It appears that acetate is a
common trace contaminant in the atmosphere and
reagents as well as in the plastic and glassware, simi-
lar to what has been observed for longer chain fatty
acids [34, 35]. To investigate this further, we sought
to determine the exact sources of background acetate
(Additional file 1: Figure S1). As we analyze acetate
in its derivatized propyl-acetate form, the background
signal that we commonly observe could be either
from propyl-acetate directly or from background acet-
ate that is derivatized to propyl-acetate during the
sample preparation. To look at the presence of back-
ground propyl-acetate, we performed an experiment
in both plastic and glassware where we analyzed the
level of propyl-acetate in reagents used for chemical
derivatization. We observed that 1-propanol has the
highest background propyl-acetate, but that it accounts
for only ~10 % of the background acetate observed in pro-
cedure blanks (PB, i.e. blank samples that have been
Fig. 3 GC chromatogram for acetate derivative (propyl-acetate). a Total ion chromatogram. b–d Extracted ion chromatograms for
12C-, U-13C-, and 2H3-acetate, respectively. Ions m/z 61, 63, and 64 (structure of ions are indicated) were used for absolute quantification
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analysis procedure), indicating that free acetate, rather
than propyl-acetate is the major contaminant. Unfortu-
nately, all the reagents are needed for the derivatization,
so we are unable to determine what reagent contains the
most background acetate. We did, however, perform the
entire derivatization and extraction procedure on blank
samples in both glass and plastic tubes. We found that in
plastic, the resulting acetate background is ~50 % higher
than in glass. Due to its convenience, we still prefer to
work with plastic tubes and we leave this decision to the
individual investigator.
Regardless of the background acetate, as the response
proved highly linear, we were able to subtract the back-
ground signal (we quantify acetate background using
blank samples that have been subjected to the entire
sample preparation and mass spec analysis procedure,
i.e., procedure blanks), resulting in a linear dynamic
range from 2 to 2000 μM for both 12C-acetate and U-
13C-acetate. The determined limit of quantification
(LOQ) for U-13C-acetate was 0.1 μM. To keep 12C-acetate
contamination to a minimum, we recommend preparing
fresh reagents regularly (weekly), and we also recommend
including procedure blanks routinely. Of note, we suggest
users to quantify their own background acetate signal as it
depends on the materials and reagents used and, there-
fore, it is very likely to be lab-specific.
We consider our approach to be an optimized alterna-
tive to other published derivatization methods, for the
rapid measurement of acetate [26–28]. An approach based
on silylation of acetate with N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) showed a
wide linear range for acetate quantification (0–
3500 μM), high repeatability and low relative standard
deviation (RSD < 5 %) [26]. It is, however, not suitable
for processing water-based samples, the multiple ex-
traction steps may lead to high background acetate
levels, and the MS run time is long for analysis of
acetate alone. An approach based on alkylation using
propyl chloroformate (PCF) is similar to ours with re-
spect to methodology and analytical performance but
uses larger reagent volumes (which increases the risk
for high acetate background levels) and longer MS run
times as it was not optimized for acetate specifically,
and it does not mention formate [27]. The published
lower limit of quantification was comparable to our
method (15 μM for current method versus 16 μM re-
ported by Zheng et al. [27]). Zheng et al. [27] reported
wider range of linear response, i.e., 16 μM–8 mM. We
did not test beyond 2 mM as we have not observed
such high levels in a physiological context. The re-
ported repeatability was observed to be very similar
with 0.54 % RSD (n = 6) reported by Zheng et al.
[27], and ~0.7 % RSD (n = 3) depending on the acet-
ate concentration, reported in current method for
standard samples (relative standard deviations summa-
rized in Additional file 1: Table S2). Finally, another
GC-MS-based method for the analysis of short-chain
fatty acids used 2,4-difluoroaniline and 1,3-dicyclocar-
bodiimide as condensation reagents, which necessi-
tated 1-h incubation step [28]. Overall, the work
presented here contributes the following, in addition
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timized method for acetate as well as an adapted
method to measure formate, (2) an in-depth discus-
sion about background acetate, its potential sources,
and how to deal with it in a practical manner, and
(3) an approach to not only measure free acetate but
also bound acetate.
The sample preparation protocol includes the addition
of sodium hydroxide to facilitate the alkylation reaction.
While this happens immediately prior to the derivatiza-
tion reaction and the samples are cooled, this could
potentially result in unwanted hydrolysis of acetylated
bio-molecules, leading to increased levels of free acetate.
To test if this occurs, we performed sample preparation
and analysis on 10 mM solutions of N-acetyl-L-aspartic
acid (NAA) and N-acetyl-L-cysteine (NAC), 1 g/L of
BSA as well as procedure blanks. As amino acid acetyl-
ation is the most abundant source of bound acetate, and
we did not observe a significant increase in signal, we
conclude that the contribution from hydrolyzed bound
acetate is negligible (Fig. 4).
Acetate quantification in biological samples
Having established that our method can accurately and
reproducibly quantify acetate, we next wanted to deter-
mine if it can reproduce previously established results.
We therefore quantified acetate in plasma from eight
healthy individuals. The plasma acetate concentrations
varied from 20 to 51 μM with a median concentration ofFig. 4 The effect of sodium hydroxide added during the derivatization
on hydrolysis of bound acetate. Whisker plot for the relative acetate
background derived from procedure blank and N-acetylated
biomolecules—BSA, N-acetyl-L-aspartate (NAA) and N-acetyl-L-cysteine
(NAC). No significant deacetylation occurs during the derivatization
procedure. Data are means ± SD of n = 5 for all conditions. Horizontal
line and dot on box plot correspond to median value and outlier,
respectively. Upper and lower end of box plot vertical line are maximum
and minimum determined values, respectively34.1 ± 9.0 μM (data not shown). This falls within the
previously published values of 41.9 ± 15.1 μM [36] and
30.4 ± 9.0 μM (Human Metabolome Database [37]).Fig. 5 Acetate uptake by normoxic and hypoxic cancer cells.
Concentration profile of U-13C-acetate in the medium of A549
cells in a normoxic and b hypoxic (1 % O2) conditions and c
uptake rates calculated from (a, b). Values are mean ± SD (n = 3)
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for the enzyme acetyl-CoA synthetase 2 (ACSS2) in me-
diating tumor growth during hypoxic and nutrient-
limited conditions [20, 21, 38]. ACSS2 “activates” acetate
to AcCoA so that it can be used for downstream meta-
bolic reactions, including lipogenesis. Indeed, addition of
U-13C-acetate to the medium of cultured cancer cells
revealed increased labeling of lipogenic AcCoA, and
consequently fatty acids, in hypoxic relative to normoxic
conditions [17, 21]. However, to what extent this in-
creased labeling is caused by an increase in acetate up-
take remains unknown. To address this, we cultured
A549 lung carcinoma cells in normoxic or hypoxic
(1 % O2) conditions in medium containing 500 μM U-
13C-acetate, and followed its concentration over time
using our new method (Fig. 5). Consistent with the ob-
served labeling of lipogenic AcCoA from U-13C-acet-
ate, a robust consumption of U-13C-acetate by hypoxic
cells was observed, as evidenced by a clear reduction in
the medium. Surprisingly, while labeling of lipogenic
AcCoA in normoxic conditions is considerably less
than in hypoxia [17, 21], normoxic cells also displayed
avid U-13C-acetate consumption. The acetate uptake
rates for hypoxic cells were with 2.5 ± 0.1 nmole/h/μL
cells (PCV) modestly higher than for normoxic cells
(1.9 ± 0.1 nmole/h/μL cells). These results suggest that
the increased labeling of lipogenic AcCoA from U-13C-
acetate in hypoxia (~3-fold increase, data not shown)
cannot be fully explained by increased acetate uptake.
Instead, the increased labeling is likely partly caused by
a drop in production of lipogenic AcCoA from glucose
in hypoxic cells, leading to inflation of the relative con-
tribution from acetate. We are in the process of investi-
gating this further.Fig. 6 Concentration of free acetate in mouse samples. Whisker plots of (a)
well as for (b) plasma and urine were obtained from C57BL/6. Snap-frozen
quantification. Data are means ± SD of tissue (n = 7) and fluid (n = 5) sampl
outlier, respectively. Upper and lower end of box plot vertical line are maxim
horizontal lines of a box are the 3rd and the 1st quartile, respectivelyFree acetate concentration in mouse tissues and fluids
In vivo isotope tracing experiments demonstrated the
utilization of exogenous acetate by tumors [20, 21], con-
firming a critical role for ACSS2 in mediating growth in
various cancers [38]. However, the availability of acetate
for solid tumors and how this varies between host or-
gans remains largely unknown. In an attempt to address
this, we analyzed tissues from multiple mouse (C57BL/6)
organs (heart, kidney, liver, lung, pancreas, spleen, thy-
mus) as well as plasma and urine (Fig. 6). Of all the
organs analyzed, the liver contained the highest con-
centration of free acetate with an average concentration
of 1.0 ± 0.1 nmole of acetate per mg of tissue (i.e.,
~1 mM), more than twice as much as any other tissue.
Nutrients absorbed by the intestine will first pass
through the liver via the portal vein. High millimolar
concentrations of acetate and other short-chain fatty
acids have been reported to be generated by gut micro-
biota [39], and this provides a rationale for the high
acetate concentration in the liver. As the concentration
of acetate in the liver is much higher than in systemic
circulation (i.e., plasma) and the lungs, which contain
the first capillary system to be perfused by blood after
liver passage, the liver appears to capture substantial
amounts of acetate for metabolic use. Acetate was also
considerably enriched in the pancreas and kidney rela-
tive to plasma, with concentrations of 0.5 ± 0.04 and
0.4 ± 0.06 nmole/mg (~0.5 and 0.4 mM), respectively.
The reason for high acetate in the pancreas remains to
be elucidated. One function of the kidneys is to clear
water-soluble excess or toxic metabolites from the
blood and considering that the acetate concentration in
urine is substantially higher than in plasma, acetate
may actually be actively excreted from the body asthe heart, kidney, liver, lung, pancreas, spleen, and thymus tissues as
tissues were ground, and tissue aliquots were used for free acetate
es. Horizontal line and dot on box plot correspond to median value and
um and minimum determined values, respectively. Upper and lower
Fig. 7 (See legend on next page.)
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Fig. 7 Quantification of (sub)cellular total acetate. a Schematic indicating what fractions were analyzed. b Western-blot showing quality of
separation of the nuclear (TBP) and residual cellular fraction (tubulin). c Total acetate in whole-cell extract or nuclear and residual cellular
fractions. d Same as (c), but expressed relative to protein amount in each fraction. e Histones (red spheres) are heavily acetylated and
acetylation controls gene expression. f Western blot of histones following acidic extraction, stained with Ponceau S. g Amount of total
acetate from acid extracted histones or nuclear fractionation. h Effect of HDAC inhibitor panobinostat on levels of acetate bound to
histones. Values are mean ± SD (n = 3)
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in other tissues with the lowest value found in the
spleen at a concentration similar to plasma. Together,
these observations highlight that the availability of acet-
ate may vary considerably between organs, which has
implications for tumor metabolism.
Analysis of bound acetate in (sub)cellular and
histone fractions
AcCoA occupies a central node in metabolism and is
involved in biomass synthesis, catabolic pathways, and
energy production. Because of this, AcCoA plays an im-
portant role in metabolic regulation [8]. This occurs in
part through acetylation of bio-molecules, including a
variety of proteins [2]. For example, acetylation of his-
tones promotes gene transcription and a correlation
between degree of histone acetylation and tumor aggres-
siveness has been observed [40]. Further evidence for
the importance of acetylation homeostasis in cancer pro-
gression comes from the observation that disrupting
acetylation dynamics by inhibiting deacetylases (i.e.,
HDACs, sirtuins) leads to potent induction of cancer cell
death [12, 15]. While several aspects of acetylation are
being extensively studied, much remains unknown about
absolute pool sizes and turnover of acetate bound to
bio-molecules in the various cell compartments, let
alone how they are affected by tumor-relevant condi-
tions. To address this, we combined our approach with
hydrolysis in basic conditions. By heating samples and
incubating them overnight with sodium hydroxide, ester
bonds hydrolyze, releasing free acetate, which can then
be derivatized and analyzed as before. Using this approach
on a whole cell extract allowed us to quantify total (bound
+ free) acetate in A549 cells at 0.38 μmole/mg total cel-
lular protein. We next asked if it would be possible to
quantify bound acetate in separate cell compartments.
We achieved a near-complete separation of the nuclear
and residual cellular fractions (combination of cytosol
and organelles other than the nucleus) using a commer-
cial nuclear isolation kit (see “Methods” section)
(Fig. 7b). We found that the bound acetate content was
approximately equal for the nuclear and residual frac-
tions (Fig. 7c). The sum of both fractions equaled
~80 % of the whole-cell measurement, which is most
likely caused by reduced recovery during fractionation,
but may also be caused by loss of free acetate.Expressing the acetate content per mg protein in each
fraction revealed that the acetylation density in the nu-
cleus is approximately threefold higher than in the re-
sidual cell fraction (Fig. 7d). Histones are known to be
heavily acetylated, and to determine how much of the
nuclear acetate was histone-bound, we compared the
results of the nuclear isolation approach with a pub-
lished acidic histone extraction protocol (Fig. 7e–g)
[29]. Both approaches gave very similar values, indicat-
ing that nearly all bound acetate in the nuclear fraction
is due to histone acetylation. Thus, histone acetylation
alone accounts for half of the total cellular acetate.
This approach towards quantifying histone bound
acetate may help to better understand the effect of his-
tone acetylation in various cancer-related studies. To
demonstrate the utility of the approach, we treated
A549 cells with panobinostat, a pan-histone deacetylase
(HDAC) inhibitor. A short, 4-h incubation with panobino-
stat caused a near doubling in the amount of histone-
bound acetate, demonstrating that histone acetylation
turnover is quite fast (Fig. 7h).
Measuring formate and other short-chain fatty acids
By modifying the derivatization agent, the method is read-
ily adaptable to other short-chain fatty acids, including
formate. Coupling formate with benzyl alcohol generates
formate derivative (benzyl formate), which can be readily
analyzed by GC-MS (see supplemental experimental pro-
cedures Additional file 1: S1). We mentioned before that
the GC-MS method for acetate analysis takes only 4 min,
with mass detector operating between 2.2 and 2.7 min.
The same method is able to analyze and quantify propion-
ate and butyrate in the form of propyl-propionate and
propyl-butyrate using the same sample derivatization
method setup as for acetate. By extending mass detector
operation time from 2.2 to 4 min, we were able to detect
the propionate and butyrate peaks eluting at 2.92 and
3.30 min, respectively. Using ions m/z 75 and 89 for pro-
pionate and butyrate, respectively, it is possible to abso-
lutely quantify these short-chain fatty acids.
Conclusions
Here, we presented a robust and high-throughput
method for absolute quantification of acetate using gas
chromatography-mass spectrometry. It is based on a
well-established chemical derivatization approach using
Tumanov et al. Cancer & Metabolism  (2016) 4:17 Page 11 of 12methyl chloroformate and facilitates stable isotope tra-
cing studies. In short, we anticipate that the analytical
methods outlined here will be valuable to the cancer me-
tabolism research community.
Additional file
Additional file 1: Table S1. Derivatization efficiency of acetate. Table S2.
Summary of relative standard deviations (RSD) for analyzed acetate
samples. S1. Protocol for formate analysis and quantification. Table S3.
GC temperature program for formate analysis. Figure S1. Assessment
of background propyl-acetate and acetate levels. (DOCX 398kb)
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